JOANNE B contact WEIDHAAS

Summary

Affiliation: Yale University
Country: USA

Publications

  1. ncbi request reprint MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy
    Joanne B Weidhaas
    Department of Therapeutic Radiology, Yale University School of Medicine, 333 Cedar Street, P O Box 208040, New Haven, CT 06520, USA
    Cancer Res 67:11111-6. 2007
  2. ncbi request reprint The let-7 microRNA reduces tumor growth in mouse models of lung cancer
    Aurora Esquela-Kerscher
    Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut 06520, USA
    Cell Cycle 7:759-64. 2008
  3. pmc A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk
    Lena J Chin
    Department of Molecular, Yale University, New Haven, Connecticut 06520, USA
    Cancer Res 68:8535-40. 2008
  4. ncbi request reprint A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer
    Jemima J Dorairaj
    Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06510, USA
    BMC Cancer 14:421. 2014
  5. ncbi request reprint The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905
    Larissa J Lee
    Department of Radiation Oncology, Brigham and Women s Hospital Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 9:e94167. 2014
  6. pmc A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis
    Olga Grechukhina
    Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA
    EMBO Mol Med 4:206-17. 2012
  7. pmc A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer
    E S Ratner
    Department of Gynecological Oncology, Yale University, New Haven, CT, USA
    Oncogene 31:4559-66. 2012
  8. pmc A Caenorhabditis elegans tissue model of radiation-induced reproductive cell death
    J B Weidhaas
    Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06520, USA
    Proc Natl Acad Sci U S A 103:9946-51. 2006
  9. ncbi request reprint A conserved RAS/mitogen-activated protein kinase pathway regulates DNA damage-induced cell death postirradiation in Radelegans
    Joanne B Weidhaas
    Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut 06520 8040, USA
    Cancer Res 66:10434-8. 2006
  10. pmc Changes in gene expression predicting local control in cervical cancer: results from Radiation Therapy Oncology Group 0128
    Joanne B Weidhaas
    Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut, USA
    Clin Cancer Res 15:4199-206. 2009

Collaborators

  • Hugh S Taylor
  • H Yu
  • S Pecorelli
  • Idhaliz Flores
  • R Lindner
  • P E Schwartz
  • J N Weitzel
  • A D Santin
  • S L Neuhausen
  • X Yao
  • Lingeng Lu
  • DAVID EISENMANN
  • Frank Slack
  • Yong Zhu
  • Steven Belinsky
  • Imran A Babar
  • Lynn D Wilson
  • James B Yu
  • Larissa J Lee
  • Jemima J Dorairaj
  • Olga Grechukhina
  • E S Ratner
  • Elena Ratner
  • T Paranjape
  • R U Muller
  • S Nallur
  • M Kato
  • Aurora Esquela-Kerscher
  • Lena J Chin
  • Stephanie King
  • Kathryn M Greven
  • David W Salzman
  • Thomas W Burke
  • Catherine Curran
  • Vinita Parkash
  • Deirdre Wall
  • Marie Wood
  • Marta Boeke
  • Harold Kim
  • David Gaffney
  • Catherine Aw Sullivan
  • Carina Preskill
  • Michael J Kerin
  • Kathryn Winter
  • Adam P Dicker
  • Kelly Underhill
  • Raleigh J Boulware
  • Tiffany Rounds
  • John Newell
  • Lyndsay Harris
  • Kim Lezon-Geyda
  • Terri McVeigh
  • Nicola Miller
  • Mohamed Uduman
  • M Glasgow
  • Y Deng
  • T J Rutherford
  • Shota Popkhadze
  • Efi Massasa
  • Rafaella Petracco
  • D Zelterman
  • L Steele
  • M Boeke
  • Trupti Paranjape
  • M C Cristea
  • R A Tassi
  • F K Keane
  • S Bellone
  • S Sand
  • D Katsaros
  • A Ravaggi
  • Elcie Chan
  • E Bignotti
  • E Gillespie
  • A Esquela-Kerscher
  • R Ullrich
  • K Keane
  • Lubna Patrawala
  • Elizabeth A Burki
  • Eva Straka
  • Trupti Kulkarni
  • Richard E Crowell
  • Kenneth K Kidd
  • Li Su
  • Daniel Zelterman
  • David Brown
  • David C Christiani
  • Rihong Zhai
  • Rajeshvari Patel
  • Andreas G Bader

Detail Information

Publications14

  1. ncbi request reprint MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy
    Joanne B Weidhaas
    Department of Therapeutic Radiology, Yale University School of Medicine, 333 Cedar Street, P O Box 208040, New Haven, CT 06520, USA
    Cancer Res 67:11111-6. 2007
    ..These findings are the first direct evidence that miRNAs can suppress resistance to anticancer cytotoxic therapy, a common feature of cancer cells, and suggest that miRNAs may be a viable tool to augment current cancer therapies...
  2. ncbi request reprint The let-7 microRNA reduces tumor growth in mouse models of lung cancer
    Aurora Esquela-Kerscher
    Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut 06520, USA
    Cell Cycle 7:759-64. 2008
    ..These findings provide direct evidence that let-7 acts as a tumor suppressor gene in the lung and indicate that this miRNA may be useful as a novel therapeutic agent in lung cancer...
  3. pmc A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk
    Lena J Chin
    Department of Molecular, Yale University, New Haven, Connecticut 06520, USA
    Cancer Res 68:8535-40. 2008
    ..The LCS6 variant allele in a KRAS miRANA complementary site is significantly associated with increased risk for NSCLC among moderate smokers and represents a new paradigm for let-7 miRNAs in lung cancer susceptibility...
  4. ncbi request reprint A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer
    Jemima J Dorairaj
    Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06510, USA
    BMC Cancer 14:421. 2014
    ..Here, we tested the hypothesis that this variant predicts tumor biology, like other 3'UTR mutations in cancer...
  5. ncbi request reprint The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905
    Larissa J Lee
    Department of Radiation Oncology, Brigham and Women s Hospital Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 9:e94167. 2014
    ....
  6. pmc A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis
    Olga Grechukhina
    Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA
    EMBO Mol Med 4:206-17. 2012
    ..These findings suggest that an inherited polymorphism of a let-7 miRNA binding site in KRAS leads to abnormal endometrial growth and endometriosis. The LCS6 polymorphism is the first described genetic marker of endometriosis risk...
  7. pmc A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer
    E S Ratner
    Department of Gynecological Oncology, Yale University, New Haven, CT, USA
    Oncogene 31:4559-66. 2012
    ..In addition, this study supports the hypothesis that these tumors have continued dependence on such 3'UTR lesions, and that direct targeting may be a viable future treatment approach...
  8. pmc A Caenorhabditis elegans tissue model of radiation-induced reproductive cell death
    J B Weidhaas
    Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06520, USA
    Proc Natl Acad Sci U S A 103:9946-51. 2006
    ..This genetic tissue model provides a valuable tool for oncology-based research and affords a platform to broaden our insight into responses to cytotoxic therapy in tissues...
  9. ncbi request reprint A conserved RAS/mitogen-activated protein kinase pathway regulates DNA damage-induced cell death postirradiation in Radelegans
    Joanne B Weidhaas
    Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut 06520 8040, USA
    Cancer Res 66:10434-8. 2006
    ..Radelegans is a platform to further define the genetic basis of the radiation response in tissues...
  10. pmc Changes in gene expression predicting local control in cervical cancer: results from Radiation Therapy Oncology Group 0128
    Joanne B Weidhaas
    Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut, USA
    Clin Cancer Res 15:4199-206. 2009
    ..To evaluate the potential of gene expression signatures to predict response to treatment in locally advanced cervical cancer treated with definitive chemotherapy and radiation...
  11. pmc The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells
    M Kato
    Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT 06520, USA
    Oncogene 28:2419-24. 2009
    ....
  12. doi request reprint Postmastectomy radiation therapy for lymph node-negative, locally advanced breast cancer after modified radical mastectomy: analysis of the NCI Surveillance, Epidemiology, and End Results database
    James B Yu
    Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520, USA
    Cancer 113:38-47. 2008
    ..The role of postmastectomy radiotherapy (PMRT) for lymph node-negative locally advanced breast carcinoma (T3N0M0) after modified radical mastectomy (MRM) with regard to improvement in survival remains an area of controversy...
  13. doi request reprint miRNA modulation of the cellular stress response
    Imran A Babar
    Yale University, Department of Molecular, Cellular and Developmental Biology, PO Box 208103, New Haven, CT 06520, USA
    Future Oncol 4:289-98. 2008
    ....
  14. ncbi request reprint MicroRNAs as a potential magic bullet in cancer
    Frank J Slack
    Yale University, Department of Molecular, Cellular and Developmental Biology, PO Box 208103, New Haven, CT 06520, USA
    Future Oncol 2:73-82. 2006
    ..The let-7 miRNA is one of a number of 'oncomirs', natural miRNA tumor suppressors in lung tissue, which may prove useful in treating lung cancer or enhancing current treatments for lung cancer...

Research Grants4

  1. Defining the Genetic Basis of the Radioresponse Using a C. elegans Tissue Model
    Joanne Weidhaas; Fiscal Year: 2007
    ..This work will use a novel model, Radelegans, to identify single-gene targets as well as test the potential of newly identified gene regulators (microRNAs) to accomplish these goals. ..
  2. Let-7 microRNAs in Lung Cancer: Altering Growth and Radioresistance
    Joanne Weidhaas; Fiscal Year: 2009
    ..In this proposal we plan experiments to learn how to harness these natural genetic growth repressors to work towards their application to cancer therapy. ..
  3. Let-7 microRNAs in Lung Cancer: Altering Growth and Radioresistance
    JOANNE B contact WEIDHAAS; Fiscal Year: 2010
    ..In this proposal we plan experiments to learn how to harness these natural genetic growth repressors to work towards their application to cancer therapy. ..